Management of Bleeding and Anticoagulation Therapy

In a patient with atrial fibrillation (AF) receiving anticoagulation therapy who has active bleeding,

it is recommended to identify the bleeding source as soon as possible.

For bleeding management, the following key information about anticoagulation therapy is essential:

Clinical effect (duration of effect since the last dose)
Antidote (directly neutralizes the drug)
Reversal therapy (indirectly reduces the drug effect)

Illustration depicting anticoagulant therapy in atrial fibrillation, comparing warfarin and NOACs with a visual representation of bleeding risk.

Vitamin K

is the antidote to warfarin,
restores synthesis of factors II, VII, IX, X (and proteins C, S),
prevents INR “rebound” after prothrombin complex concentrate,
onset of effect: 6–24 hours.

Prothrombin complex concentrate

is reversal therapy for warfarin,

it is an off-label reversal therapy for apixaban, rivaroxaban, edoxaban,

contains high concentrations of factors II, VII, IX, X → rapid INR correction,
prothrombin complex concentrate can be:

3-factor (II, IX, X),
4-factor (II, VII, IX, X) – preferred for reversal of warfarin and NOAC,

onset of effect: 10–30 minutes.

Fresh frozen plasma

is reversal therapy for warfarin,
contains all coagulation factors at physiological concentrations,
has a slower onset and requires large volume administration,

1,000–2,000 ml is administered (depending on patient body weight),

onset of effect: 4–6 hours.

Bleeding in a patient with AF receiving NOAC:

If the patient is bleeding and took the last dose within 4 hours,
activated charcoal or gastric lavage is recommended.

Warfarin – Management of bleeding
Intervention	Onset of effect	Standard dose
Prothrombin complex concentrate	10 – 30 min	Life-threatening bleeding: 50 IU/kg intravenous (max. 3,000 – 5,000 IU depending on product) According to INR (approximate): INR 2 – 4: 25 IU/kg INR 4 – 6: 35 IU/kg INR > 6: 50 IU/kg
Fresh frozen plasma	4 – 6 hours	15 ml/kg intravenous
Vitamin K	6 – 12 hours intravenous 24 hours oral	Severe bleeding: 5 – 10 mg intravenous slowly (≈ 30 min) concomitantly with prothrombin complex concentrate INR ≥ 8 without bleeding: 2.5 – 5 mg oral (or intravenous) INR 4.5 – 8 without bleeding: consider 1 – 2.5 mg oral in patients at high bleeding risk

Laboratory parameters that provide approximate information on the effect/overdose of anticoagulation therapy:

Warfarin – INR (International Normalized Ratio)
Dabigatran – dTT (diluted Thrombin Time)
Rivaroxaban – anti-Xa test calibrated for rivaroxaban
Apixaban – anti-Xa test calibrated for apixaban
Edoxaban – anti-Xa test calibrated for edoxaban

Routine monitoring of NOAC is not required.

Anticoagulation therapy (onset, duration of effect, and antidote)
Drug	Onset of effect	Clinical effect after last dose	Antidote / reversal therapy
Warfarin	3 – 5 days	3 – 5 days	Vitamin K, PCC, FFP
Dabigatran	1 – 3 hours	24 – 36 hours	Idarucizumab
Apixaban	2 – 4 hours	24 hours	Andexanet alfa, PCC (off-label)
Rivaroxaban	2 – 4 hours	24 hours	Andexanet alfa, PCC (off-label)
Edoxaban	1 – 2 hours	24 hours	PCC (off-label)
LMWH	2 – 4 hours	12 – 24 hours	Partially neutralized by protamine

LMWH – Low-Molecular-Weight Heparin (Enoxaparin, Dalteparin, Nadroparin). PCC – Prothrombin Complex Concentrate (Prothrombin complex concentrate). FFP – Fresh Frozen Plasma. Off-label means use of a drug outside an approved indication.

Antiplatelet therapy has a very short half-life but a very long clinical effect,

because it mostly binds irreversibly to platelets until platelets are cleared.
Platelets are cleared within 7–10 days.
New platelets then form in sufficient numbers to normalize coagulation.

Antiplatelet drugs have a short plasma half-life, but their clinical effect lasts long.

Most agents (aspirin, clopidogrel, prasugrel) bind irreversibly to platelets; inhibition persists until platelet clearance.

Exception: ticagrelor is a reversible platelet inhibitor; recovery of coagulation takes 3–5 days.

After discontinuation, it takes approximately 7–10 days for enough new platelets to form and normal coagulation function to be restored.

Antiplatelet therapy (elimination half-life and clinical effect)
Drug	Elimination half-life	Clinical effect after last dose
Aspirin	20 min	7 – 10 days
Clopidogrel	6 hours	7 – 10 days
Ticagrelor	7 – 9 hours	3 – 5 days
Prasugrel	7 hours	7 – 10 days

Approximate annual risk of major bleeding in patients with HAS-BLED score < 2.

Major bleeding risk with HAS-BLED < 2
Therapy	Major bleeding risk (per year)
Warfarin	1.1 – 2.3 %
NOAC	1.0 – 2.0 %
Aspirin	0.5 – 1.5 %
Dual antiplatelet therapy (DAPT)	1.5 – 2.5 %
No antithrombotic therapy	< 0.3 %

Management of bleeding and anticoagulation therapy	Class
In active bleeding (major or non-major), immediate interruption of anticoagulation therapy and investigation for the bleeding source is recommended.	I
In non-major bleeding (during warfarin therapy), discontinuation of warfarin and waiting for INR to fall below 2 and for bleeding to stop is recommended.	I
In non-major bleeding (during warfarin therapy), vitamin K (oral or intravenous) should be administered, and INR should be allowed to fall below 2.	IIa
In major bleeding (during warfarin therapy), prothrombin complex concentrate should be administered.	IIa
In non-major bleeding (during NOAC therapy), withholding NOAC for 1–2 days and waiting for bleeding to stop is recommended.	I
In non-major bleeding (during NOAC therapy), activated charcoal or gastric lavage should be administered (if the patient took NOAC within 4 hours).	IIa
In major bleeding (during NOAC therapy), an antidote or prothrombin complex concentrate should be administered.	IIa